Zyprexa: Advanced Antipsychotic Treatment for Symptom Control
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.61 | $78.26 (0%) | 🛒 Add to cart |
| 60 | $1.91 | $156.52 $114.38 (27%) | 🛒 Add to cart |
| 90 | $1.68 | $234.78 $151.36 (36%) | 🛒 Add to cart |
| 120 | $1.56 | $313.04 $187.48 (40%) | 🛒 Add to cart |
| 180 | $1.45
Best per pill | $469.56 $260.58 (45%) | 🛒 Add to cart |
| Product dosage: 2.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.39 | $35.26 (0%) | 🛒 Add to cart |
| 120 | $0.34 | $47.01 $41.28 (12%) | 🛒 Add to cart |
| 180 | $0.30 | $70.52 $54.18 (23%) | 🛒 Add to cart |
| 270 | $0.27 | $105.78 $73.10 (31%) | 🛒 Add to cart |
| 360 | $0.26
Best per pill | $141.04 $92.88 (34%) | 🛒 Add to cart |
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $3.07 | $92.02 (0%) | 🛒 Add to cart |
| 60 | $2.25 | $184.04 $135.02 (27%) | 🛒 Add to cart |
| 90 | $1.99 | $276.06 $178.88 (35%) | 🛒 Add to cart |
| 120 | $1.85 | $368.08 $221.88 (40%) | 🛒 Add to cart |
| 180 | $1.71
Best per pill | $552.12 $307.88 (44%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.76 | $45.58 (0%) | 🛒 Add to cart |
| 90 | $0.69 | $68.37 $61.92 (9%) | 🛒 Add to cart |
| 120 | $0.65 | $91.16 $78.26 (14%) | 🛒 Add to cart |
| 180 | $0.62 | $136.74 $111.80 (18%) | 🛒 Add to cart |
| 270 | $0.60 | $205.11 $161.68 (21%) | 🛒 Add to cart |
| 360 | $0.59
Best per pill | $273.48 $211.56 (23%) | 🛒 Add to cart |
| Product dosage: 7.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.78 | $53.32 (0%) | 🛒 Add to cart |
| 60 | $1.40 | $106.64 $84.28 (21%) | 🛒 Add to cart |
| 90 | $1.28 | $159.96 $115.24 (28%) | 🛒 Add to cart |
| 120 | $1.22 | $213.28 $146.20 (31%) | 🛒 Add to cart |
| 180 | $1.15 | $319.92 $207.26 (35%) | 🛒 Add to cart |
| 270 | $1.11
Best per pill | $479.88 $300.14 (37%) | 🛒 Add to cart |
Synonyms | |||
Similar products
Zyprexa (olanzapine) is an atypical antipsychotic medication specifically engineered to target and modulate neurotransmitter activity in the central nervous system. It is indicated for the treatment of schizophrenia, bipolar I disorder, and as an adjunct therapy in treatment-resistant depression. With its well-established receptor affinity profile, Zyprexa offers clinicians a reliable option for managing acute and maintenance phases of severe psychiatric conditions. Its pharmacokinetic properties support consistent therapeutic levels with once-daily dosing, enhancing patient adherence and long-term stability.
Features
- Active ingredient: Olanzapine
- Available formulations: Oral tablets, orally disintegrating tablets (Zyprexa Zydis), and intramuscular injection
- Receptor binding profile: High affinity for serotonin 5-HT₂A, dopamine D₂, muscarinic, histamine H₁, and adrenergic α₁ receptors
- Half-life: Approximately 30 hours, supporting once-daily dosing
- Metabolism: Primarily hepatic via CYP1A2 and CYP2D6 isoenzymes
- Bioavailability: Not significantly affected by food intake
Benefits
- Effective reduction of positive and negative symptoms in schizophrenia
- Rapid stabilization of acute manic or mixed episodes in bipolar I disorder
- Decreased relapse rates in maintenance therapy for both schizophrenia and bipolar disorder
- Adjunctive efficacy in treatment-resistant major depressive disorder
- Flexible administration options including fast-dissolving formulations for improved compliance
- Established long-term safety profile with extensive clinical data
Common use
Zyprexa is primarily prescribed for the management of schizophrenia in adults and adolescents aged 13-17 years. It is also indicated for acute mixed or manic episodes associated with bipolar I disorder and maintenance treatment of bipolar disorder. Additionally, it is used in combination with fluoxetine for treatment-resistant depression and depressive episodes associated with bipolar I disorder. Off-label uses may include behavioral symptoms of dementia (with caution), Tourette’s syndrome, and certain anxiety disorders, though these applications require careful risk-benefit assessment.
Dosage and direction
Initial dosing for schizophrenia in adults typically begins at 5-10 mg once daily, with maintenance doses ranging from 10-20 mg daily. For bipolar mania, starting doses of 10-15 mg daily are common. The orally disintegrating tablets (Zyprexa Zydis) should be placed on the tongue immediately after opening the blister pack. Intramuscular formulation is reserved for acute agitation in schizophrenia and bipolar mania at doses of 2.5-10 mg. Dosage adjustments are necessary in elderly patients, those with hepatic impairment, or when co-administered with CYP1A2 inhibitors like fluvoxamine. Regular therapeutic drug monitoring is recommended during maintenance therapy.
Precautions
Patients should be monitored for weight gain and metabolic parameters including blood glucose and lipid profiles. Regular assessment for extrapyramidal symptoms and tardive dyskinesia is essential. Caution is advised in patients with cardiovascular disease, cerebrovascular disease, or conditions predisposing to hypotension. Use with care in those with history of seizures or conditions that may lower the seizure threshold. Elderly patients with dementia-related psychosis treated with antipsychotics show increased mortality risk. Patients should avoid alcohol consumption and be cautioned about operating machinery until response is established.
Contraindications
Zyprexa is contraindicated in patients with known hypersensitivity to olanzapine or any component of the formulation. It should not be used in patients with narrow-angle glaucoma due to anticholinergic effects. Concurrent use with other central nervous system depressants may potentiate sedation and respiratory depression. The intramuscular formulation is contraindicated in patients with known hypersensitivity to olanzapine and should not be administered intravenously or subcutaneously.
Possible side effect
Common adverse reactions (≥5%) include: weight gain, somnolence, dizziness, increased appetite, hyperprolactinemia, and peripheral edema. Significant metabolic effects may include hyperglycemia, dyslipidemia, and development of metabolic syndrome. Extrapyramidal symptoms occur less frequently than with typical antipsychotics but may include parkinsonism, akathisia, and dystonic reactions. Rare but serious effects include neuroleptic malignant syndrome, tardive dyskinesia, venous thromboembolism, and pancreaticitis. Orthostatic hypotension, especially during initial dose titration, requires careful monitoring.
Drug interaction
Zyprexa may potentiate effects of other central nervous system depressants including benzodiazepines, opioids, and alcohol. CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) may increase olanzapine concentrations, while inducers (carbamazepine, omeprazole, smoking) may decrease levels. Antihypertensive agents may have enhanced hypotensive effects when combined with olanzapine. Levodopa and dopamine agonists may have diminished efficacy due to dopamine receptor antagonism. Caution is advised with drugs that prolong QT interval, though olanzapine itself has minimal effect on cardiac repolarization.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is接近 the time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed administration. Consistent daily dosing is important for maintaining therapeutic drug levels, particularly given Zyprexa’s 30-hour half-life. Healthcare providers should be consulted if multiple doses are missed to determine appropriate management strategy.
Overdose
Symptoms of overdose may include drowsiness, slurred speech, tachycardia, hypotension, and extrapyramidal symptoms. In severe cases, respiratory depression, coma, or delirium may occur. There is no specific antidote for olanzapine overdose. Management involves supportive care including gastric lavage if presented early, activated charcoal, and maintenance of adequate cardiorespiratory function. Cardiovascular monitoring should continue for at least 24 hours due to the drug’s prolonged elimination half-life. Hemodialysis is not expected to be effective due to high protein binding.
Storage
Store at controlled room temperature 20-25°C (68-77°F). Protect from light and moisture. Keep in original container with lid tightly closed. Orally disintegrating tablets should remain in blister packages until immediately before use. Keep out of reach of children and pets. Do not use after expiration date printed on packaging. Proper disposal of unused medication should follow local regulations, typically through medication take-back programs.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Zyprexa is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual response to medication may vary, and treatment decisions should be based on comprehensive clinical assessment. Patients should discuss all potential risks and benefits with their prescribing physician and report any adverse effects promptly.
Reviews
Clinical trials demonstrate Zyprexa’s efficacy in reducing PANSS scores by approximately 30-40% in schizophrenia patients compared to placebo. Maintenance studies show significantly reduced relapse rates with olanzapine versus placebo (p<0.001). In bipolar disorder, response rates of 65-75% have been observed in manic episodes. Real-world evidence supports these findings, though observational data highlight weight gain and metabolic concerns as significant treatment considerations. Patient-reported outcomes indicate improved quality of life measures particularly in social functioning and symptom control, though individual experiences with side effects vary considerably.